SEARCH

SEARCH BY CITATION

References

  • 1
    Bortolotti F, Verucchi G, Cammà C, Cabibbo G, Zancan L, Indolfi G, et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 2008; 134: 1900-1907.
  • 2
    González-Peralta R, Langham MR, Jr., Andres JM, Mohan P, Colombani PM, Alford MK, Schwarz KB. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2009; 48: 630-635.
  • 3
    Rodrigue JR, Balistreri W, Haber B, Jonas MM, Mohan P, Molleston JP, et al. Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children. HEPATOLOGY 2011; 53: 1468-1475.
  • 4
    Comanor L, Minor J, Conjeevaram HS, Roberts EA, Alvarez F, Bern EM, et al. Impact of chronic hepatitis B and interferon-alfa therapy on growth of children. J Vir Hepat 2001; 8: 139-147.
  • 5
    Gottrand F, Michaud L, Guimber D, Ategbo S, Dubar G, Turck D, Farriaux JP. Influence of recombinant interferon alpha on nutritional status and growth pattern in children with chronic viral hepatitis. Eur J Pediatr 1996; 155: 1031-1034.
  • 6
    Schwarz KB, Gonzalez-Peralta RP, Murray KF, Molleston JP, Haber BA, Jonas MM, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011; 140: 450-458.e451.
  • 7
    Murray KF, Rodrigue JR, González-Peralta RP, Shepard J, Robuck PR, Schwarz KB; for the PEDS-C Clinical Research Network. Design of the PEDS-C trial: pegylated interferon ± ribavirin for children with chronic hepatitis C viral infection. Clin Trials 2007; 4: 661-673.
  • 8
    Addo OY, Himes JH. Reference curves for triceps and subscapular skinfold thicknesses in US children and adolescents. Am J Clin Nutr 2010; 91: 635-642.
  • 9
    Hui SL, Gao S, Zhou XH, Johnston CC, Jr., Lu Y, Glüer CC, et al. Universal standardization of bone density measurements: a method with optimal properties for calibration among several instruments. J Bone Miner Res 1997; 12: 1463-1470.
  • 10
    Kelly TL, Wilson KE, Heymsfield SB. Dual energy X-ray absorptiometry body composition reference values from NHANES. PLoS ONE 2009; 4: e7038.
  • 11
    Burrows TL, Martin RJ, Collins CE. A systematic review of the validity of dietary assessment methods in children when compared with the method of doubly labeled water. J Am Diet Assoc 2010; 110: 1501-1510.
  • 12
    Schofield W. Predicting basal metabolic rate, new standards, and review of previous work. Hum Nutr Clin Nutr 1985; 39C( Suppl 1): 5-41.
  • 13
    Sallis JF, Haskell WL, Wood PD, Fortmann SP, Rogers T, Blair SN, et al. Physical activity assessment methodology in the Five-City Project. Am J Epidemiol 1985; 121: 91-106.
  • 14
    Kuloğlu Z, Kansu A, Demirçeken F, Arici ZS, Berberoğlu M, Ocal G, Girgin N. The influence of interferon-alpha and combination interferon-alpha and lamivudine therapy on height and weight in children with chronic hepatitis B infection. J Pediatr Endocrinol Metab 2007; 20: 615-620.
  • 15
    González-Peralta R, Kelly DA, Haber B, Molleston J, Murray KF, Jonas MM, et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. HEPATOLOGY 2005; 42: 1010-1018.
  • 16
    Sokal EM, Bourgois A, Stéphenne X, Silveira T, Porta G, Gardovska D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol 2010; 52: 827-831.
  • 17
    Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010; 52: 501-507.
  • 18
    Piche T, Schneider SM, Tran A, Benzaken S, Rampal P, Hebuterne X. Resting energy expenditure in chronic hepatitis C. J Hepatol 2000; 33: 623-627.
  • 19
    Hamer C. The impact of combination therapy with peginterferon alpha-2a and ribavirin on the energy intake and body weight of adult hepatitis C patients. J Hum Nutr Diet 2008; 21: 486-493.